Arnatar Therapeutics Presents Clinical Data from Healthy Volunteers at the American College of Cardiology Annual Scientific Session (ACC.26)
SAN DIEGO, CA, March 29, 2026 -- Arnatar Therapeutics, a biotechnology company pioneering RNA-based therapies for severe and underserved diseases, today announced the presentation of clinical data from its ART101 program in healthy volunteers at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.26), held March 28–30, 2026, in New Orleans, Louisiana.
In a first-in-human, randomized, placebo-controlled Phase 1 study in healthy subjects, ART101, a GalNAc-conjugated siRNA targeting hepaticangiotensinogen (AGT), demonstrated robust, dose-dependent, and durable target engagement. Single subcutaneous doses achieved up to 93% reductions in serum AGT levels, reaching near-maximal suppression by three weeks and sustained over the 24-week observation period. Consistent with its mechanism of action, ART101 also produced dose-dependent and durable reductions in blood pressure. The treatment was well tolerated, with no serious adverse events, treatment discontinuations, or injection site reactions reported. These data support ART101 as a promising long-acting therapeutic approach for blood pressure control.
“We are encouraged by the robust, dose-dependent and durable reductionsin angiotensinogen, as well as the consistent blood pressure lowering observed in this first-in-human study of ART101, along with its favorable safety and tolerability profile,” said Roger Liu, MD, Chief Medical Officer of Arnatar Therapeutics. “These data validate AGT as a highly compelling upstream target in the renin-angiotensin system and highlight the potential of ART101as a long-acting therapeutic approach for patients with hypertension.”
About Arnatar Therapeutics
Arnatar Therapeutics is a clinical-stage biotechnology company redefining the possibilities of RNA medicine. With its proprietary DARGER™ platform, Arnatar uniquely integrates best-in-class siRNA gene silencing with first-in-class antisense oligonucleotides (ASOs) that upregulate protein expression. This dual-modality platform empowers Arnatar to develop RNA medicines that either silence harmful disease driversthrough siRNA or restore essential protein function through up-regulating ASOs, opening new therapeutic possibilities for previously untreatable conditions.The company’s pipeline spans across cardiometabolic, liver, kidney, and central nervous system diseases, targeting areas of high unmet medical need. Founded by leaders in RNA therapeutics and backed by leading biotech investors, Arnatar iscommitted to transforming RNA innovation into life-changing, programmable medicines for patients worldwide.
Investor Contact:
Chris Nardo
LifeSci Advisors, LLC
cnardo@lifesciadvisors.com
646-517-2499